Next-generation technology provides human genome sequence

First complete sequence of an individual African genome

Next-generation technology provides human genome sequence

genome_300.jpg
Heterozygous 844 bp deletion in NA07340 relative to the reference, detected by anomalously spaced read pairs (orange) compared to regularly spaced read pairs (green). The presence of regularly spaced pairs across the entire region is indicative of heterozygosity at this locus.

Researchers at the Sanger Institute have announced that a study carried out in collaboration with Illumina scientists has yielded the first complete and publicly available sequence of an African individual human genome. The study, published in Nature, was executed using next-generation Illumina sequencing technologies to sequence the human genome with 99.9 per cent accuracy. The DNA sequenced was taken from the HapMap project and belongs to an individual from the Yoruba of Ibadan, Nigeria.

It is anticipated that advances in individual genome sequencing technologies will allow scientists to identify genetic differences between people that may contribute to differences in health and disease. Using new technologies to sequence the genome, scientists have been able identify 4 million single base changes or single-nucleotide polymorphisms (SNPs) - 26 per cent of which had not been previously identified - and 400 000 larger scale variants in the sequence.

"We have reached the point where we can begin to study individual human genomes routinely at the level of each of their three billion base pairs. The methods we developed for this project can now be applied to develop a deep catalogue of human variation that will underpin the next phase of human genetic research."

Richard Durbin of the Wellcome Trust Sanger Institute

The 1000 Genomes Project, co-led by Dr Durbin, which launched in January 2008, will sequence the genomes of over 1000 people to discover all human genetic variants that occur at more than 1 per cent frequency.

DNA sequencing projects have historically been carried out using technology that reads around 96 sections of DNA 400-800 base pairs long simultaneously. The sequencing technology used in this study instead reads more than 30 million sections of DNA around 35 base pairs long. These reads are reassembled by mapping them against the Human Genome Project's reference DNA (NCBI build 36.1), thereby creating an accurate whole genome for the given individual.

For this project the data were collected in only eight weeks and for around $300,000, compared to the eight years and over $300 million for the first human genome sequence produced in 2000.

"It is now possible to economically and efficiently sequence human genomes to discover and profile human genetic variation."

David Bentley, Vice-President and Chief Scientist of DNA Sequencing at Illumina

The Sanger Institute's study appears in the same edition of Nature as the first complete genetic sequence of a person of Han Chinese descent, carried out by the Beijing Genomics Institute (BGI) and the first complete genetic sequence of a cancer patient, carried out by Washington University. This is the first time three individual genomes have been simultaneously published in one edition of a journal marking a widespread adoption of high-throughput sequencing technologies to map individual human genomes accurately, economically and widely.

Notes to Editors
Publications
  • Accurate whole human genome sequencing using reversible terminator chemistry.

    Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J et al.

    Nature 2008;456;7218;53-9

Funding

This research was supported in part by The Wellcome Trust, the Biotechnology and Biological Sciences Research Council, the BBSRC Applied Genomics LINK Programme and the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health. S. Balasubramanian and D. Klenerman are inventors and founders of Solexa Ltd.

Selected Websites
Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7900 607793

Recent News

Low doses of radiation promote cancer-capable cells
New research in mice helps to understand the risks around exposure to low doses of radiation, such as CT scans and x-rays
Chan Zuckerberg Initiative boosts Human Cell Atlas research at the Sanger Institute
Seed Networks projects will focus on specific tissues, such as the thymus, lung, liver, kidney and immune system
Widely-available antibiotics could be used in the treatment of ‘superbug’ MRSA
Genomic analysis shows that a significant number of strains are susceptible to penicillin combined with clavulanic acid